170 related articles for article (PubMed ID: 8559495)
21. [Treatment of anemia in patients with chronic renal insufficiency undergoing hemodialysis with recombinant human erythropoietin: 12 months' experience].
de Sousa FT; Prata MM; Barbas JV; dos Santos JP
Acta Med Port; 1990; 3(6):347-52. PubMed ID: 2089856
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of hypertension induced by erythropoietin in patients on hemodialysis.
Yamakado M; Umezu M; Nagano M; Tagawa H
Clin Invest Med; 1991 Dec; 14(6):623-9. PubMed ID: 1794212
[TBL] [Abstract][Full Text] [Related]
23. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis.
Anavekar NS; Tleyjeh IM; Anavekar NS; Mirzoyev Z; Steckelberg JM; Haddad C; Khandaker MH; Wilson WR; Chandrasekaran K; Baddour LM
Clin Infect Dis; 2007 May; 44(9):1180-6. PubMed ID: 17407036
[TBL] [Abstract][Full Text] [Related]
24. [Arterial hypertension in patients with chronic kidney insufficiency in hemodialysis with erythropoietin].
Martins Prata M; Teixeira de Sousa F; Barbas J; Vinhaś J; Marques da Costa A
Rev Port Cardiol; 1990 Feb; 9(2):119-23. PubMed ID: 2346662
[TBL] [Abstract][Full Text] [Related]
25. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
[TBL] [Abstract][Full Text] [Related]
26. The haemodynamic effects of correction of anaemia in haemodialysis patients using recombinant human erythropoietin.
Abdulhadi MH; Fouad-Tarazi FM; Thomas T; Bravo EL; Paganini EP
Nephrol Dial Transplant; 1990; 5 Suppl 1():102-8. PubMed ID: 2129437
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients.
Caravaca F; Pizarro JL; Arrobas M; Cubero JJ; García MC; Perez-Miranda M
Kidney Int; 1994 Mar; 45(3):845-51. PubMed ID: 8196287
[TBL] [Abstract][Full Text] [Related]
28. Hemodynamic effects of anemia correction by recombinant human erythropoietin in predialysis patients with renal failure.
Sapojnikov M; Veksler A; Yagil Y; Kogan J; Turkot S; Boris G; Oren S
Ren Fail; 2005; 27(2):199-203. PubMed ID: 15807186
[TBL] [Abstract][Full Text] [Related]
29. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
[TBL] [Abstract][Full Text] [Related]
30. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis.
Berns JS; Rudnick MR; Cohen RM
Clin Nephrol; 1992 May; 37(5):264-7. PubMed ID: 1606777
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
[TBL] [Abstract][Full Text] [Related]
32. Effects of recombinant human erythropoietin (rHuEPO) on nutritional status of hemodialysis patients: investigation of direct anabolic effects of rHuEPO.
Usuba T; Kuno T; Higuchi T; Kikuchi F; Nagura Y; Kanmatsuse K; Takahashi S
Nihon Jinzo Gakkai Shi; 1994 Nov; 36(11):1288-95. PubMed ID: 7853762
[TBL] [Abstract][Full Text] [Related]
33. Long-term effects of treatment with recombinant human erythropoietin on haemodynamics and tissue oxygenation in patients with renal anaemia.
Nonnast-Daniel B; Deschodt G; Brunkhorst R; Creutzig A; Bahlmann J; Shaldon S; Koch KM
Nephrol Dial Transplant; 1990; 5(6):444-8. PubMed ID: 2122322
[TBL] [Abstract][Full Text] [Related]
34. Erythropoietin treatment of idiopathic myelofibrosis.
Aloe Spiriti M; Latagliata R; Avvisati G; Battistel V; Montefusco E; Spadea A; Petti MC
Haematologica; 1993; 78(6):371-3. PubMed ID: 8175031
[TBL] [Abstract][Full Text] [Related]
35. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
[TBL] [Abstract][Full Text] [Related]
36. [Influence of parathormone level on the doses of human recombinant erythropoietin in haemodialysed patients].
Zelichowski G; Olszowska A; Lubas A; Wańkowicz Z
Pol Merkur Lekarski; 2002 Nov; 13(77):373-5. PubMed ID: 12621751
[TBL] [Abstract][Full Text] [Related]
37. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
[TBL] [Abstract][Full Text] [Related]
38. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin.
London GM; Zins B; Pannier B; Naret C; Berthelot JM; Jacquot C; Safar M; Drueke TB
Kidney Int; 1989 Nov; 36(5):878-82. PubMed ID: 2615194
[TBL] [Abstract][Full Text] [Related]
39. [Platelet antiaggregation and hemorrhagic risk in hemodialysis].
Sánchez Perales MC; Vázquez E; García Cortés MJ; Borrego FJ; Borrego J; Pérez del Barrio P; Liébana A; Gil JM; Viedma G; Pérez Bañasco V
Nefrologia; 2002; 22(5):456-62. PubMed ID: 12497747
[TBL] [Abstract][Full Text] [Related]
40. Influence of the 6-month anemia therapy with erythropoietin on renal function and some hemodynamic parameters in predialysis patients.
Tomczak-Watras W; Strózecki P; Zuchora Z; Szefer J; Manitius J
Pol Arch Med Wewn; 2009; 119(1-2):45-51. PubMed ID: 19341178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
